The latest EDMA figures indicate that total revenues for the European In Vitro Diagnostic industry grew by 4.2% in 2008, to reach €10.02 billion. The German market remains, by far, the largest contributor with revenues of over €2 billion and France and Italy are the second and third largest markets respectively with an annual revenue of €1.6 billion each.
http://www.edma-ivd.be/fileadmin/upl_documents/Annual_Report/2009/EDMA_2010-07-16_Annual_Report.pdf
http://www.edma-ivd.be/fileadmin/upl_documents/Annual_Report/2009/EDMA_2010-07-16_Annual_Report.pdf
Så lige der var en jobannonce idag 15/09/10 hvor BioPorto søger en QA kemiker :
http://www.stepstone.dk/jobs--QA-kemiker-Gentofte-Bioporto-Diagnostics-A-S--297252-inline.html?cs=true
Spæændende!
http://www.stepstone.dk/jobs--QA-kemiker-Gentofte-Bioporto-Diagnostics-A-S--297252-inline.html?cs=true
Spæændende!
15/9 2010 21:08 fillandkill 0
33523 Det lyder da til at de har gang i et eller andet på grusbakken... hvad mon det kan være..
16/9 2010 11:27 DrueAgurken 233549 Roche Estimates 2009 In Vitro Diagnostics Market of $48.2 Billion USD
Based on Roche 2009 Annual Report - “Figures on market growth, market share and market size are estimates based on company and independent reports and Roche analysis.”
The 2009 Worldwide In Vitro Diagnostics market is worth 40 billion dollars.
In addition, Roched makes the following estimates:
Professional Diagnostics (Laboratory and POC IVD): $28 billion dollars with growth of +5% (includes but not limited immunoassay, clinical chemistry, coagulation, cardiovascular and excludes blood glucose, molecular, research and cancer diagnostics)
Diabetes (blood glucose and insulin delivery systems): $6.5 billion dollars with growth of 0%.
Molecular: $3.7 billion dollars growing at +12%.
Applied Science: $8 billion dollars growing at +8%.
Cancer: $2 billion dollars.
It is interesting to note that if you add-up all the 5 segments classified above, the amount totals $48.2 billion; which is different from the $40 billion total IVD market estimate. So this is a discrepancy that Roche folks did not notice while writing their 2009 annual report.
Kilde:
http://xaviernogue.com/business/blog/?p=65
16/9 2010 11:28 DrueAgurken 233550 2009 Market of In Vitro Diagnostics (Fiscal; in Million US dollars and % growth in reported currency with respect 2008)
Roche: $9,492, %4.1
Siemens: $4,712, %9.5
Johnson and Johnson: $4,400, %1.0
Abbott: $3,578, %0.1
Beckman Coulter: $3,261, %5.2
Becton Dickinson (BD):
bioMerieux: $1,651, %10
Sysmex:
BioRad:
Werfen Group: Cannot disclose figures unless they are public (I work for IL)
Olympus:
Cytyc:
GenProbe:
Biosite:
Cepheid:
Grifols: $1,233, %12
Radiometer: $450, 7%
Abaxis: $106, 5%
Nanosphere: $2, 57%
Samme kilde som ovenstående.
Roche: $9,492, %4.1
Siemens: $4,712, %9.5
Johnson and Johnson: $4,400, %1.0
Abbott: $3,578, %0.1
Beckman Coulter: $3,261, %5.2
Becton Dickinson (BD):
bioMerieux: $1,651, %10
Sysmex:
BioRad:
Werfen Group: Cannot disclose figures unless they are public (I work for IL)
Olympus:
Cytyc:
GenProbe:
Biosite:
Cepheid:
Grifols: $1,233, %12
Radiometer: $450, 7%
Abaxis: $106, 5%
Nanosphere: $2, 57%
Samme kilde som ovenstående.
